AR and breast cancer: As was observed with enzalutamide, abiraterone also increased the sensitivity of both AR+ ZR75-1 (Figure 4A) and AR- MDA MB 231 (Figure 4B) breast cancer cells to CTL-mediated lysis, confirming the ability of ADT to increase the sensitivity of breast cancer cells to immune-mediated killing regardless of AR status.